Aenova Expands Production with USD 22 Million Investment

German CDMO, Aenova, has announced a USD 22mn investment to upgrade its Bad Aibling, Germany, site. Capacity for its blister packaging lines has been increased to 220 million blisters, annually, whilst a new strip packaging line increased effervescent output to 420 million tablets a year.

The company plans to further expand its Bad Aibling site by including a new explosion-proof fluid bed granulator for organic granulation.

Aenova is expanding its Bad Aibling site. With a total investment of around 20 million euros in new production and packaging lines, the site offers a modern, high-volume infrastructure for the production of effervescent products and blister packaging.

Aenova is a leading global contract development and manufacturing organisation for the pharmaceutical and healthcare industries with approximately 4,000 employees and 14 production sites. At the Bad Aibling site, the competence center for blister packaging / third party packaging and for high volumes of effervescent products within the Aenova network, a total of around 20 million euros is now being invested in modernizing the machinery. Another new blister line was just put into operation in February 2025.

With ultra-modern, fast blister lines and a capacity of around 220 million blisters per year, customers in the blister and third-party packaging sector can now be served even better. In the area of effervescent products, another new strip packaging line was successfully commissioned at the beginning of the year. This means that two strip lines and one tube line are now available for effervescent products. More than 420 million effervescent tablets per year can now be produced and packaged in Bad Aibling. Further investments will follow, including a new explosion-proof fluid bed granulator for organic granulation. As a result, the site has a modern infrastructure that enables shorter delivery times and can grow with the customer.

"With these major investments, we can offer significantly increased production capacity on state-of-the-art, high-speed equipment and position ourselves as a preferred and strategic partner for our customers," explains Thomas Lemke, Managing Director of the Aenova site in Bad Aibling.

For more, please find the original story source here.

Previous
Previous

Almac Group's £65M Investment in Northern Ireland Manufacturing Facility

Next
Next

Terumo’s Ultimaster™ Stents Gain MDR Approval for High-Bleeding Risk Patients